Pilgrim Partners Asia Pte Ltd Takes $65,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Pilgrim Partners Asia Pte Ltd bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, Holdings Channel.com reports. The fund bought 880 shares of the medical research company’s stock, valued at approximately $65,000.

Several other large investors have also recently bought and sold shares of EW. Harbor Capital Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB lifted its position in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its stake in Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $3,702,000. Finally, Avanza Fonder AB acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $4,845,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on EW. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Piper Sandler increased their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $69.39 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a 50 day simple moving average of $71.74 and a 200 day simple moving average of $70.62. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The firm has a market cap of $40.79 billion, a P/E ratio of 9.95, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock worth $4,513,064 over the last three months. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.